Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

scientific article

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2016.70.7398
P932PMC publication ID5455807
P698PubMed publication ID28199818

P50authorDarren R FeldmanQ56588360
Toni K ChoueiriQ88414622
Eric J SmallQ97531370
Michael J. MorrisQ38329744
Susan HalabiQ42896002
P2093author name stringDaniel J George
Joel Picus
Ben L Sanford
Shaker Dakhil
M Dror Michaelson
Thomas Olencki
Olwen Hahn
Meghara K Walsh
P2860cites workNegative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.Q45778660
Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.Q45945576
Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United StatesQ54192985
Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted TherapyQ86570241
Contemporary Treatment of Metastatic Renal Cell CarcinomaQ26740594
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogeneQ28202069
Sunitinib versus interferon alfa in metastatic renal-cell carcinomaQ28282757
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialQ29615711
Pazopanib versus sunitinib in metastatic renal-cell carcinomaQ33409916
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyQ33510317
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.Q33880227
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyQ34007924
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.Q34217927
Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaQ34495684
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccineQ34537725
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsQ34978329
Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinomaQ36287092
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinomaQ36551653
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screenQ36954859
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaQ36959106
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.Q37711680
Targeted therapies for renal cell carcinoma: review of adverse event management strategiesQ37974894
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaQ38835745
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Q38859789
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinomaQ38870929
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthQ39472261
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaQ41316099
Kidney cancer, version 3.2015.Q41407499
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectrenal cell carcinomaQ1164529
metastatic renal cell carcinomaQ19000948
P304page(s)591-597
P577publication date2016-11-14
P1433published inJournal of Clinical OncologyQ400292
P1476titleCabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
P478volume35

Reverse relations

cites work (P2860)
Q914034278p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival
Q91799952A comprehensive review of protein kinase inhibitors for cancer therapy
Q47143379A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma
Q90763649A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
Q47571632A step towards predicting checkpoint inhibitor response in kidney cancer
Q59811941Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports
Q88030898Aiming for complete responses in renal-cell carcinoma
Q96635014An Electronic Health Record Text Mining Tool To Collect Real-World Drug Treatment Outcomes: A Validation Study In Metastatic Renal Cell Carcinoma Patients
Q92564139Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Q95841180Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
Q57154768Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Q50573517Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016.
Q90428644Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma
Q42364404Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Q92985062Biomarkers in renal-cell carcinoma: building on clinical paradigms
Q64231724Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
Q64060174C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas
Q90711501Cabozantinib Reverses Renal Cell Carcinoma-Mediated Osteoblast Inhibition in Three-Dimensional Co-culture In Vitro and Reduces Bone Osteolysis In Vivo
Q92533805Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
Q38746778Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Q57481747Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Q38668871Cabozantinib for the treatment of kidney cancer
Q64040149Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Q42257155Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
Q97519474Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Q54980900Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Q48273276Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation
Q52650529Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
Q50139906Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Q89338718Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints
Q37672483Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Q89520843Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?
Q90811571Cancer du rein métastatique : recommandations et perspectives en 1re ligne
Q99608128Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers
Q90711847Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Q47737687Clinical development of mTor inhibitors for renal cancer
Q47103399Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review
Q50030018Combination therapies for patients with metastatic renal cell carcinoma.
Q52661758Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Q38673512Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation
Q90614066Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
Q52611170Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma
Q47567121Cytoreductive nephrectomy: A medical oncologist's perspective
Q47177700Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
Q90233305Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
Q64902254Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy.
Q92204700Economic burden of renal cell carcinoma among older adults in the targeted therapy era
Q91986120Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
Q89074133Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology
Q48171089Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
Q96811961Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Q92382571Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis
Q96811951Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma
Q38676794Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma
Q49550673Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib.
Q59340207Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
Q90600541First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options
Q91792703First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis
Q100426629From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Q90590637Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Q94526293Immune checkpoint inhibitors in genitourinary malignancies
Q89521181Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma
Q98466280Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
Q92400515Incidence and risk of fatigue in cancer patients treated with MET inhibitors: A systematic review and meta-analysis
Q102214589Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin
Q99614963Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
Q56889461Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Q50042576Kidney cancer in 2017: Challenging and refining treatment paradigms.
Q38754614Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy
Q100457384Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib
Q90428559Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?
Q90651821Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019
Q49953442Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
Q49573718Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.
Q90000428Management of metastatic renal cell carcinoma: The complexity of choice
Q92001564Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Q57153919Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Q64092301Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy
Q92422466MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge
Q47550490Multimodal treatment of advanced renal cancer in 2017.
Q42315473My personal highlights of ESMO 2016.
Q89860576New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies
Q54990172New treatment options for metastatic renal cell carcinoma.
Q52644831Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Q96132776Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab
Q89682905Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Q91347054Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
Q47713191Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Q92350780PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Q91116230Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Q98945511Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Q61813148Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
Q88328786Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Q58104090Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery
Q100457390Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
Q93349430RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer
Q92442591Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
Q50297707Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies
Q39157961Renal cell carcinoma: molecular characterization and evolving treatment paradigms.
Q89493245Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position
Q98291421Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Q92815283Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
Q89393258Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Q98466875Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma
Q92793810Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis
Q90493724S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma
Q57803800Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Q52682465Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review
Q96811967Sequencing Therapies for Metastatic Renal Cell Carcinoma
Q57071032Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
Q91844057Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
Q54977510Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Q92372125Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
Q50209991TKI 2.0 - changes in the medical treatment of renal cell carcinoma
Q39425380Targeted therapies for renal cell carcinoma
Q64253749Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"
Q100455154Targeting the HIF2-VEGF axis in renal cell carcinoma
Q92826118The Changing Therapeutic Landscape of Metastatic Renal Cancer
Q56889715The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma
Q92181246The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases
Q58103455The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study
Q55378351The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria.
Q92763321The effect of a treatment delay on outcome in metastatic renal cell carcinoma
Q39253187The role of c-Met in prognosis and clinicopathology of renal cell carcinoma: Results from a single-centre study and systematic review
Q52645823The role of tumor microenvironment in resistance to anti-angiogenic therapy.
Q91765160Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Q93139113Towards individualized therapy for metastatic renal cell carcinoma
Q90811595Traitement des métastases osseuses du cancer du rein
Q54987382Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
Q54976476Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer.
Q47726014Treatment of renal cell carcinoma: Current status and future directions
Q58572132Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study
Q92004328Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer
Q92247732Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma
Q90160018Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
Q54982000When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report.
Q104517656[French ccAFU guidelines - update 2020-2022: management of kidney cancer]
Q89475892[Risk-adapted therapy for metastatic renal cell carcinoma]

Search more.